Treatment Options in Relapsed/Refractory Multiple Myeloma: Caring for the Patient During the First Relapse and Beyond

Treatment Options in Relapsed/Refractory Multiple Myeloma: Caring for the Patient During the First Relapse and Beyond
Treatment Options in Relapsed/Refractory Multiple Myeloma: Caring for the Patient During the First Relapse and Beyond
CME, CPE
Sagar Lonial, MD, FACP
Release Date: August 22, 2018
Expiration Date: August 22, 2019

While evolving pharmacologic options continue to improve the management of relapsed/refractory multiple myeloma (RRMM), the selection of therapy following a first relapse and beyond is critical for improving prognoses and outcomes. This activity will address the efficacy and safety of current and emerging therapies for RRMM as well as strategies for overcoming challenges that clinicians often encounter when integrating novel agents into practice.

Provided by MediCom Worldwide, Inc.
This activity is supported by educational grants from Amgen, Bristol-Myers Squibb, Celgene Corporation, and Takeda Oncology
Begin, Earn CreditView Only, No CreditGet Certificate